This article was originally published in The Gray Sheet
Excimer laser manufacturers renew vows for merger; the latest agreement calls for Advanced Interventional Systems (LAIS) shareholders to receive .80282 shares of Spectranetics stock for each LAIS share, giving them 45% ownership of the new company. The merger, subject to "customary conditions" and shareholder approval, is expected to close in four months. Following the merger, Spectranetics' President and CEO Robert DePasqua would serve as President, CEO and a director of the new firm, while LAIS director David Goldsmith would serve as chairman. AIS Chairman and CEO Robert Wall has resigned. An earlier acquisition offer by Spectranetics and merger proposal by LAIS, which were floated after an initial merger agreement fell through, were terminated in December ("The Gray Sheet" Dec. 20, In Brief)
You may also be interested in...
Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.
Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection
Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.